Yahoo1d
2 Reasons to Buy Amgen Stock, and 1 Reason to Be Cautious
While Amgen's (NASDAQ: AMGN) shares have underperformed the market over the past 12 months, climbing 19.7% compared to the ...
What’s Happening With Amgen Stock?
As an aside, in the tech space, see What’s Happening With Snap Stock? Although the recent Amgen update didn’t bode well with ...
STAT2d
AbbVie’s stumble, Amgen’s tumble, and more election fallout
On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...
Medscape5h
B-Cell Depleting Drug Shows Benefit in IgG-Related Disease
Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...
The weight-loss frenzy is making some pharma stocks much more volatile. Will the drama continue?
The excitement around the new weight-loss industry is overtaking other disease areas and portfolios for publicly traded ...
FierceBiotech4d
Hidden data on obesity prospect wipe $12B off Amgen market cap
A hidden tab in an Excel spreadsheet published nine months ago has wiped $12 billion off Amgen’s market cap. The tab ...
Amgen says no concerns around weight loss drug's bone density data after stock falls
Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...
Amgen’s Uplizna shows potential efficacy in rare inflammatory diseases
Amgen (AMGN) announced the presentation of new data across its rare disease portfolio and pipeline at the annual American College of ...
Hosted on MSN4d
Amgen dismisses bone density concerns related to its new weight-loss drug
(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, ...
Fintel on MSN1d
Wolfe Research Initiates Coverage of Amgen (AMGN) with Peer Perform Recommendation
Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Amgen (NasdaqGS:AMGN) with a Peer Perform ...